Coya Therapeutics Secures Health Canada Approval to Begin ALS Trial
I'm PortAI, I can summarize articles.
Coya Therapeutics Inc. has received Health Canada's approval for its Clinical Trial Application for COYA 302, a treatment for ALS. This approval allows the company to activate clinical trial sites in Canada, enhancing patient recruitment for the ALSTARS Trial alongside ongoing U.S. sites.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments